Systemic Therapy and Stereotactic Body Radiotherapy in Oligoprogressive Breast Cancer or Lung Cancer

1. Progression-free survival in NSCLC was found to be significant with HR 0.41 compared to breast cancer which was non-significant with HR 0.78. 2. Grade 2 or worse adverse events occurred 41% in the standard-of-care group vs 62% in the SBRT group. Evidence Rating Level: 1 (Excellent) Study Rundown: The treatment paradigm for metastatic cancer

Related Keywords

,Rating Level ,Comprehensive Treatment ,Oligometastatic Cancers ,Long Term Results ,Oligometastatic Cancer ,Radiation Therapy ,Stereotactic Body Radiotherapy ,Chronic Disease ,Oncology ,